NCT03051100View on ClinicalTrials.gov

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

January 19, 2017

Primary Completion Date

June 1, 2017

Study Completion Date

July 5, 2017

Conditions
Hypercholesterolemia
Interventions
DRUG

Bempedoic acid 180mg

bempedoic acid 180 mg

DRUG

Ezetimibe 10mg

ezetimibe 10 mg

DRUG

Atorvastatin 20mg

atorvastatin 20 mg

OTHER

Placebo

placebo

Trial Locations (11)

23451

Hampton Roads Center for Clinical Research, Virginia Beach

27518

PMG Research of Cary, Cary

27609

PMG Research of Raleigh, Raleigh

27804

PMG Research of Rocky Mount, Rocky Mount

28144

PMG Research Salisbury, Salisbury

28209

PMG Research of Charlotte, Charlotte

28277

Sensenbrenner Primary Care, Charlotte

28401

PMG Research of Wilmington, Wilmington

28601

PMG Research of Hickory, Hickory

29464

PMG Research of Charleston, Mt. Pleasant

61820

PMG Research of Christie Clinic, Champaign

Sponsors
All Listed Sponsors
lead

Esperion Therapeutics, Inc.

INDUSTRY